Kardigan to Present Late-Stage Cardiovascular Pipeline and AI-Driven Insights at ACC.26
Kardigan, a company focused on transforming heart health through innovative drug development, has announced multiple presentations at the ACC.26. The event will take place from March 28 to March 30, 2026, in New Orleans and is one of the most prominent global gatherings for cardiovascular professionals, researchers, and clinicians.
At this year’s meeting, Kardigan will showcase new data from across its entire cardiovascular (CV) pipeline, including late-stage clinical programs and preclinical research. A major highlight will be the presentation of late-breaking Phase 2 data from the KARDINAL study evaluating tonlamarsen in patients with uncontrolled hypertension. In addition, Kardigan’s subsidiary, Prolaio, will present findings from its LINK-HF2 trial, demonstrating the potential of continuous monitoring and advanced analytics in improving heart failure management.
Advancing Cardiovascular Drug Development
Kardigan’s participation at ACC.26 reflects its commitment to addressing unmet needs in cardiovascular care through a combination of innovative therapeutics and data-driven insights. The company’s research spans multiple disease areas, including hypertension, heart failure, and cardiomyopathies, with a focus on developing personalized treatment approaches.
According to company leadership, presenting data across all three late-stage programs at a single major conference underscores the strength and breadth of Kardigan’s pipeline. These presentations also highlight the company’s collaborative approach, working closely with clinical investigators to generate meaningful evidence that can improve patient outcomes.
Spotlight on Tonlamarsen in Uncontrolled Hypertension
One of the most anticipated presentations at ACC.26 is the late-breaking session featuring Phase 2 results from the KARDINAL study of tonlamarsen. This investigational therapy is being developed for patients with uncontrolled hypertension, a condition that remains a significant global health challenge.
hypertension affects millions of people worldwide and is a major risk factor for heart disease, stroke, and kidney complications. Despite the availability of multiple treatment options, many patients struggle to achieve adequate blood pressure control, highlighting the need for new therapeutic approaches.
Tonlamarsen is designed to target angiotensinogen, a key component of the renin-angiotensin system that regulates blood pressure. By reducing angiotensinogen levels, the therapy aims to provide a novel mechanism for lowering blood pressure in patients who do not respond adequately to existing treatments.
The KARDINAL Phase 2 study results will be presented in a prestigious late-breaking clinical trials session, reflecting the importance and potential impact of the findings. This presentation is expected to provide new insights into the efficacy and safety of tonlamarsen, as well as its potential role in the future management of uncontrolled hypertension.
Preclinical Research Supporting Tonlamarsen
In addition to clinical data, Kardigan will present preclinical findings that further support the development of tonlamarsen. These studies explore the effects of a liver-targeted antisense oligonucleotide (ASO) against angiotensinogen in animal models.
The research demonstrates that targeting angiotensinogen can blunt increases in systemic blood pressure induced by corticosteroids. This suggests potential applications not only in chronic hypertension but also in acute and severe cases where rapid blood pressure control is critical.
These findings contribute to a growing body of evidence supporting angiotensinogen modulation as a promising therapeutic strategy in cardiovascular medicine.
Innovations in Heart Failure Monitoring: The LINK-HF2 Trial
Kardigan’s subsidiary, Prolaio, will present multiple analyses from the LINK-HF2 trial, a multicenter randomized study focused on improving heart failure management through continuous monitoring and predictive analytics.
heart failure is a complex condition characterized by the heart’s inability to pump blood effectively. It is associated with frequent hospitalizations, high healthcare costs, and significant morbidity and mortality.
The LINK-HF2 trial investigates the use of remote monitoring technologies, including continuous electrocardiogram (ECG) and activity tracking, combined with artificial intelligence-driven predictive analytics. The goal is to identify early signs of clinical deterioration and enable timely intervention.
One of the key presentations will focus on how AI-enabled monitoring can detect changes in heart failure risk before symptoms become severe. This proactive approach has the potential to reduce hospitalizations and improve patient outcomes by allowing clinicians to intervene earlier.
Secondary Insights from Continuous Monitoring
A secondary analysis of the LINK-HF2 trial will also be presented, highlighting how continuous monitoring reveals dynamic changes in patient health following hospital discharge.
The findings suggest that vital signs and physiological parameters stabilize over time as patients recover and undergo medication adjustments. By capturing these trends in real time, clinicians can better understand patient responses to treatment and optimize care strategies.
This research underscores the value of integrating digital health technologies into cardiovascular care, enabling a more personalized and data-driven approach to managing chronic conditions.
Ataciguat and Calcific Aortic Valve Disease
Kardigan will also present preclinical data on ataciguat, another investigational therapy in its pipeline. The research focuses on calcific aortic valve disease, a condition characterized by the progressive calcification and narrowing of the aortic valve.
The study demonstrates that direct activation of oxidized soluble guanylate cyclase (sGC) with ataciguat can reduce osteogenic activation and modulate key signaling pathways involved in disease progression. These findings suggest that ataciguat may have the potential to slow or prevent the progression of valve calcification.
While still in the preclinical stage, this research highlights Kardigan’s efforts to address a wide range of cardiovascular conditions through innovative therapeutic approaches.
Danicamtiv in Dilated Cardiomyopathy
Another important presentation at ACC.26 will feature Phase 2 data on danicamtiv, a therapy being investigated for patients with dilated cardiomyopathy.
dilated cardiomyopathy is a condition in which the heart becomes enlarged and weakened, reducing its ability to pump blood effectively. It can lead to heart failure and other serious complications.
The data being presented come from an open-label extension study, providing insights into the long-term effects of danicamtiv treatment. These findings are expected to contribute to a better understanding of how the therapy may improve cardiac function and patient outcomes.
A Comprehensive Approach to Cardiovascular Innovation
Kardigan’s presentations at ACC.26 collectively demonstrate a comprehensive approach to cardiovascular innovation. By combining drug development with advanced data analytics and digital health technologies, the company is working to redefine how cardiovascular diseases are treated and managed.
The integration of personalized medicine, continuous monitoring, and novel therapeutic mechanisms represents a significant shift in the field. Rather than relying solely on traditional treatment models, Kardigan is exploring ways to tailor interventions to individual patient needs and disease dynamics.
Looking Ahead
The data to be presented at ACC.26 highlight the growing momentum behind Kardigan’s pipeline and its commitment to advancing cardiovascular care. From late-stage clinical trials to cutting-edge digital health solutions, the company is contributing to a new era of precision medicine in cardiology.
As cardiovascular diseases continue to be a leading cause of death worldwide, innovations like those being developed by Kardigan and Prolaio are essential for improving outcomes and reducing the global burden of disease.
The upcoming presentations will not only provide valuable scientific insights but also foster collaboration within the cardiovascular community. By engaging with researchers, clinicians, and industry leaders at ACC.26, Kardigan aims to accelerate the development and adoption of new therapies that can make a meaningful difference in patients’ lives.
About Kardigan
Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve. The company is based in South San Francisco, California and Princeton, New Jersey.
About Prolaio
Prolaio, a subsidiary of Kardigan, is a cardiovascular clinical intelligence company dedicated to advancing today’s cardiology research and care ecosystem. The company was created by cardiologists and cardiovascular scientists specifically to address the world’s number one cause of death, cardiovascular disease. Its FDA-cleared software integrates real world clinical data and proprietary algorithms to deliver data driven insights to empower researchers, physicians, and product developers. By combining scientific rigor with cutting edge technology, Prolaio aims to expedite clinical trials and support patient outcomes across cardiology therapeutic areas
